Monograph Details
|
|
Poisoning & Drug Dependence
> Addiction/dependence
|
|
CAMPRAL |
| Manufacturer |
|
Forest Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
GABA/taurine analogue. |
| Generic Name |
|
Acamprosate calcium 333mg; e-c tabs. |
| Indications |
|
Maintenance of abstinence from alcohol in alcohol-dependent patients who are abstinent at treatment initiation, in conjunction with psychosocial support. |
| Children |
|
Not recommended. |
| Adults |
|
666mg 3 times daily. Renal impairment (CrCl 30–50mL/min): initially 333mg 3 times daily. Begin therapy during abstinence; continue during relapse. |
| Contraindications |
|
Severe renal impairment (CrCl≤30mL/min). Sulfite allergy. |
| Precautions |
|
Moderate renal impairment (CrCl 31–50mL/min); reduce dose. Not a treatment for withdrawal symptoms. Monitor for suicidal ideation. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
GI upset, myalgia/arthralgia, headache, rash, syncope, impotence, edema, palpitations; rare: kidney failure, suicidality. |
| How Supplied |
|
Tabs—180 |
|
|
|
|
